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Tacrolimus has proven to be a potent immunosuppressive 
agent in liver transplantation (LT). Its introduction has 
led to significandy less frequent and severe acute rejection. 
Uttle is known about the rate of chronic rejection (CR) in 
primary LT using tacrolimus therapy. The aim of the 
present study is to examine the long-term incidence ofCR, 
risk factors, prognostic factors, and outcome after CR. 
The present study evaluated the development of CR in 
1,048 consecutive adult primary liver allograft recipients 
initiated and mosdy maintained on tacrolimus-based 
immunosuppressive therapy. They were evaluated with a 
mean follow-up of 77.3 ± 14.7 months (range, 50.7 to 
100.1 months). To assess the impact of primary diagnosis 
on the rate and outcome of CR, the population was 
divided into 3 groups. Group I included patients with 
hepatitis C virus (HCV)- or hepatitis B virus (HBV)-in-
duced cirrhosis (n = 312); group II included patients 
diagnosed with primary biliary cirrhosis (PBC), primary 
sclerosing cholangitis (PSC) , or autoimmune hepatitis 
(AIH; n = 217); and group III included patients with all 
other diagnoses (n = 519). Overall, 32 of 1,048 patients 
(3.1 %) developed CR. This represented 13 (4.1%), 12 
(5.5%), and 7 patients (1.3%) in groups I, II, and III, 
respectively. The relative risk for developing CR was 3.2 
times greater for group I and 4.3 times greater for group II 
compared with group III. This difference was statistically 
significant (P = .004). The incidence of acute rejection 
and total number of acute rejection episodes were signif-
icandy greater in patients who developed CR compared 
with those who did not (P < .0001). Similarly, the mean 
donor age for CR was significandy older than for patients 
without CR (43.0 v 36.2 years; P = .02). Thirteen of the 
32 patients (40.6%) who developed CR retained their 
original grafts for a mean period of 54 ± 25 months after 
diagnosis. Seven patients (21.9%) underwent re-LT, and 
12 patients (38.3%) died. Serum bilirubin levels and the 
presence of arteriopathy, arterial loss, and duct loss on 
liver biopsy at the time of diagnosis of CR were signifi-
candy greater among the 3 groups of patients. In addition, 
patient and graft survival for group I were significandy 
worse compared with groups II and III. We conclude that 
CR occurred rarely among patients maintained long term 
on tacrolimus-based immunosuppressive therapy. When 
steroid use is controlled, the incidence of acute rejection, 
mean donor age, HBV- and/or HCV-induced cirrhosis, or 
a diagnosis of PBC, PSC, or AIH were found to be predic-
tors of CR. Greater values for serum bilirubin level, duct 
loss, arteriopathy, arteriolar loss, and presence ofHCV or 
HBV were found to be poor prognostic factors for the 3 
groups; greater total serum bilirubin value (P = .05) was 
the only factor found to be significant between patients 
who had graft loss versus those who recovered. (Liver 
TranspI2001;7:623-630.) 
T he results of liver transplantation (L T) have improved significantly over the past 2 decades 
with improvements in surgical techniques and postop-
erative management and the introduction of cyclospor-
ine (CSA).1,2 However, chronic rejection (CR) occurs in 
2% to 20% of successful liver transplant recipients 
treated with CsA, and re-LT may be necessary. 1·6 Even 
after re-L T, the recurrence rate of CR is as high as 
90%,7 The introduction of tacrolimus into primary LT 
has resulted in a significant reduction in the rate of 
acute rejection.8.12 Additional studies report that up to 
70% of cases of CR occurring with CsA-based therapy 
may be halted or reversed after the initiation of tacroli-
mus therapy.13.17 Although there are reports suggesting 
a reduction in the rate of CR among tacrolimus-treated 
patients compared with those maintained on CsA ther-
apy,8,18 relatively little is known about the rate ofCR 
with long-term tacrolimus therapy. The aim of the 
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present study is to examine the incidence and risk fac-
tors for the development of CR among patients on 
long-term tacrolimus therapy and study the clinical 
outcome with prognostic factors. 
Methods 
Patients 
Between April 1990 and June 1994, a total of 1,048 adults 
(aged> 18 years) undetwent primary LT on tacrolimus-
based immunosuppressive therapy. The tacrolimus treatment 
protocol has been described in detail elsewhere.! 0, 19-23 Briefly, 
patients who underwent LT up to August 1991 were admin-
istered intravenous tacrolimus at a dose of 0.1 mg/kg/d; 
patients who underwent L T after that date were administered 
a dose of 0.05 mg/kg/d. Oral tacrolimus therapy was com-
menced when bowel function returned, usually after 2 to 5 
days. The first 118 patients (11.2%) were administered only 
baseline steroid therapy at 20 mg/ d, the next 718 patients 
(68.5%) were administered intravenously 1 g methylpred-
nisone, and the remaining 212 patients (20.2%) were admin-
istered 1 g of intravenous methylprednisolone at the time of 
LT and an additional total dose of 600 mg of methylpred-
nisolone, tapered over the next 5 days. 
All patients were followed up until death or July 1998. 
Mean follow-up was 77.3 ::!:: 14.7 months (range, 50.7 to 
100.1 months). Indications for LT are listed in Table 1. 
Donor characteristics, transplant recipient hepatitis serologi-
cal test results, and clinical courses (including changes in 
immunosuppression and survival) were evaluated retrospec-
tively. The baseline steroid dose was reduced according to 
history of rejection, and in 70% of the patients, steroid ther-
apy was discontinued at the end of the first year. All patients 
were maintained on tacrolimus therapy. Less then 5% of 
patients were converted to CsA therapy for neurotoxiciry, and 
approximately 80% were converted back to tacrolimus ther-
apy in the event of subsequent mild acute cellular rejection. 
Liver biopsies were performed for an increase in biochemical 
parameters indicative of hepatic dysfunction. Protocol liver 
biopsies were not performed. Patients who underwent L T for 
hepatitis B virus (HBY) infection were administered hyper-
immune HBV globulin prophylaxis for 6 months, whereas 
patients with hepatitis C virus (HCy) were not administered 
prophylaxis. 
Pathological Evaluation 
During the follow-up period, 5,252 post-LT biopsy speci-
mens were available for evaluation. Pathologists who had no 
knowledge of the patients' clinical courses carefully coded all 
specimens for CR using the International Banff criteria with 
the National Institute of Diabetes and Digestive and Kidney 
Diseases guidelines.24-26 Details of histopathologic findings in 
most of these patients are presented elsewhere,l8 
No. of Patients 
Diagnosis (%) 
Group I 
HCV 221 (21) 
HBV 91 (8.6) 
Group I total 312 (29.8) 
Group II 
PBC 98 (9.3) 
PSC 81 (7.7) 
A1H 38 (3.6) 
Group II total 217 (20.9) 
Group III 
Alcohol abuse 174 (16) 
Cryptogenic cirrhosis 164 (15.6) 
Hepatic neoplasm 
benign/malignant 51 (4.8) 
Hemochromatosis 20 (1.9) 
ai-Antitrypsin deficiency 18 (1.7) 
Acute hepatitis 16 (1.5) 
Secondary biliary cirrhosis 12 (1.1) 
Budd-Chiari 7 (0.7) 
Other 46 (4.4) 
Unknown 11 (1.0) 
Group III total 519 (49.5) 
Total 1,048 
Statistical Analysis 
Statistical analysis included basic descriptive statistics, Chi-
squared and non parametric tests, and modeling techniques, 
including logistic and Cox proportional hazard regression. 
Models were derived using stepwise regression, with a signif-
icance of .05 for a feature to remain in the model. Time-
dependant covariates were used when appropriate. Analyses 
were performed using Statistical Analysis System for Win-
dows, version 8.0 (SAS Institute, Cary, NC). 
Results 
Incidence of CR 
Biopsy specimens from 32 patients (21 men, 11 women; 
3.1 % of the study population) showed evidence of CR. 
The mean time from L T to the first histological sign of 
CR was 15.6 ::!: 19.2 months (median, 6.75 months; 
range, 0.6 to 83.22 months). 
Clinical Outcome 
Thirteen patients recovered without re-LT with rela-
tively stable allograft function at a mean follow-up of 
54 ::!: 25 months (median, 74 months; range, 11.3 to 
93.3 months) after the diagnosis of CR. Mean biliru-
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bin, aspartate aminotransferase (AST), alanine amino-
transferase (AL T), alkaline phosphatase, and ),-glu-
tamyltransferase (GGT) values at intervals after the 
diagnosis of CR are listed in Table 2. CR was managed 
by augmenting baseline immunosuppression; changes 
are listed in Table 2. The dose of tacrolimus or cortico-
steroids was increased in 8 of 13 and 6 of 13 patients, 
respectively. Three patients were administered myco-
phenolate mofetil, and the dose of azathioprine was 
doubled in 1 patient. Seven patients underwent re-LT 
at a mean interval of 2.2 ± 2.7 months (median, 0.8 
months; range, 0.6 to 4.0 months) after the diagnosis of 
CR. Twelve patients not considered for re-LT died. 
Causes of death included sepsis (n = 3), Kaposi's sar-
coma (n = 2), fungal infection (n = 2), infection with 
cytomegalovirus (CMV; n = 1), HIV (n = 1), replicat-
ing HBV (n = 1), recurrent hepatitis C with renal 
failure (n = 1), and a history of noncompliance (n = 1). 
The mean time to death was 17.04 ± 23.0 months 
(median, 4.8 months; range, 0.46 to 77.1 months) after 
the diagnosis of CR. 
Risk Factors for the Development of CR 
Patients who developed CR were compared with those 
who did not with respect to primary diagnosis, occur-
rence of acute rejection, HLA mismatching, CMV 
infection, and donor age. Changes in baseline immu-
nosuppression were also evaluated among patients who 
developed CR. 
Primary diagnosis. To examine the impact of primary 
diagnosis, the study population was divided into 3 
groups. Group I consisted of patients infected with 
either HCV or HBV. Patients in group II had been 
diagnosed with primary biliary cirrhosis (PBC), pri-
mary sclerosing cholangitis (PSC), or autoimmune hep-
atitis (AIH), and group III included patients with other 
diagnoses at the time ofLT (Table 1). The incidence of 
CR was significantly greater among patients in group I 
(n = 13; 4.2%) or group II (n = 12; 5.5%) compared 
with those in group III (n = 7; 1.3%; P = .004). 
Relative risks were 3.2 times greater (confidence inter-
val, 1.2 to 9.5) for group I and 4.3 times greater (con-
fidence interval, 1.5 to 13) for group II compared with 
group III (Table 3). 
Acute rejection. There was a significant difference in 
freedom from acute rejection among patients who did 
(n = 32) or did not (n = 1,016) develop CR (12.5% v 
50.0%, respectively; P = .0001; Table 4. Also, greater 
than 3 episodes of rejection was documented in 25% of 
patients with CR compared with 4.2% in the non-CR 
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Table 3. Rate ofCR in Relatiortto Cause and Clini~alMvtco~ 
95% 
Rate Relative Confidance 
Presence of Disease ofCR' P Risk Interval 
Group I (n = 312) 
HCV+ HBV 13 (4.2) .004 3.17 1.2-9.5 
Group II (n = 217) 
PBC + PSC + AIH 12 (5.5) .004 4.28 1.5-13 
Group III (n = 519) 
Othet than HeV, 7 (1.3) .004 Reference group 
HBV. PBC, PSc, 
AIH 
Total (n = 1,048) 32 (3.1) 
• Values expressed as number (percent) unless otherwise noted. 
had experienced at least 1 episode of acute rejection; 2 
patients had experienced 3 or more episodes. 
Donor age. There was a significant difference in 
mean donor age among patients who did or did not 
develop CR (43::':: 14.7 v 36.2::':: 15.9 years; P = .02). 
Mean donor ages among patients who recovered, 
underwent re-L T, or died after the diagnosis of CR 
were 3S.7 ::':: 14.7,54.0::':: 14.2, and 41.0::':: 12.5 years, 
respectively. 
Steroid induction dose. A steroid induction dose of 
either 20 mg, 1,000 mg, or 1,000 mg plus a 600-mg 
taper made no difference in the rate of CR (P = .07). 
HLA matching and/or mismatching. The mean number 
of HLA antigen mismatches at class I (2.93 v 2.97) or 
matching on class II loci (0.33 v 0.31) was not signifi-
cantly different between the respective groups (P = .79 
and P = .S9, respectively). 
CMV hepatitis. A diagnosis of CMV hepatitis was 
made on liver biopsy by the presence of cytomegaloviral 
Died Recovered Patient Survival Graft Survival 
Without Without Post-CR at 5 Post-CR at 5 





6 3 30.7 23 
3 6 72.7 54.5 
3 4 85.6 85.6 
12 13 
inclusions by immunoperoxidase staining. The overall 
rate of CMV hepatitis was 4.3% (46 patients). How-
ever, in patients who developed CR, the rate was 12.5% 
(4 of 32 patients) versus 4.1 % (42 of 1,016 patients) in 
patients who did not develop CR. This was found to be 
significant (P = .02) on univariate analysis. 
Using multivariable analysis and controlling for ste-
roid induction, the number of acute rejection episodes 
(P = .000l), donor age (P = .005), HCV- and/or 
HBV-induced cirrhosis (P = .03), and diagnosis of 
PBC, PSC, or AIH (P = .OOS) were found to be pre-
dictors of CR. 
Maintenance of immunosuppression. Reduction or discon-
tinuation of baseline maintenance immunosuppression 
occurred in 14 of 32 patients (43.S%), who subse-
quently developed CR. Four patients were noncompli-
ant with the immunosuppressive regimen. Immuno-
suppression was reduced or discontinued in the 




Table 4. Episod¢s of ACllteB,ejection,in Relation to Rate of Co:and_cat~cEjme 
.. -- -
-- -
Clinical Outcome Post-CR 
NoCR Died Without Recovered Without 
(n = 1,016) CR(n = 32) Re-LT (n = 7) Re-LT (n = 12) Re-LT (n = 13) 
frequency of acute 
rejection 
0 508 (50) 4 (12.5) 0 2 (16.7) 2 (15.4) 
1 . 373 (36.7) 12 (37.5) 4 (57.2) 4 (33.3) 4 (30.8) 
2 93 (9.2) 8 (25) I (14.3) 4 (33.3) 3 (23.1) 
"':3 42 (4.2) 8 (25.0) 2 (28.6) 2 (16.7) 4 (30.8) 
Mean rejection per 
patient 0.69 ::':: 0.86 1.8 ::':: 1.3 2.1 ::':: 1.9 1.5 ::':: 1.0 1.7 ::':: 1.1 
P <.0001 .72 
NOTE. Values expressed as number (percent). 
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Figure 1. Patient survival for groups I, II, and III after 
CR. 
infection (n = 5), or neurotoxicity (n = 1). Six of these 
14 patients are currently alive with a functioning graft, 
3 patients underwent re-LT, and 5 patients died. All 7 
patients in group III who experienced reduction or dis-
continuation of immunosuppression developed CR. 
Conversely, 3 of the 13 patients in group I (23%) and 
4 of the 12 patients in group II (33%) developed CR 
(P = .003). 
Prognostic Factors 
Patient and graft survival were significantly better 
among patients in groups II and III compared with 
those in group I (P = .01; Figs. 1 and 2). Biochemical 
profiles and histopathologic findings were evaluated at 
the time of diagnosis of CR to predict risk factors for 
graft loss, defined as re-L T or death. 
Liver function profile. Mean serum bilirubin level was 
significantly greater among patients with CR who 
required re-LT or died compared with those who 
retained the graft (P = .05). Mean differences in AST, 
ALT, alkaline phosphatase, and GGT levels among the 
groups did not achieve statistical significance. 
Histopathologic evaluation. Detailed histopathologic 
findings in most of these patients have been previously 
reported. 18 Duct damage and duct atrophy were seen in 
the majority of patients who developed CR. The rate of 
duct loss was significantly greater for patients who 
required re-LT (P = .011). 
Arteriopathy was noted in biopsy samples retrieved 
from only 3 of 32 patients with CR, all of whom 
required re-LT. Conversely, arteriopathy was not evi-
dent among 25 patients who either recovered or died 
after the development of CR. Arteriolar loss occurred in 
5 of 32 patients; 2 of these patients recovered and the 
remaining 3 patients received a second liver allograft. 
Data suggest that arteriopathy with duct loss was asso-
ciated with a poorer outcome than duct damage or duct 
100 __ --~~------------------------~ 
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-+-Group II ~------npc-=---;l"DKlD;:;l::::t==~==:f 
"Grou III o-==:::::;==--r---I----I-----I--~ 
o 3 12 24 36 48 60 
Months post Chronic rejection 
Figure 2. Graft survival for groups I, II, and III after CR. 
atrophy alone. Arteriopathy and duct loss were noted in 
12 patients, and arteriopathy alone was noted in 3 
patients. 
Discussion 
The reported incidence of CR is berween 2.4% and 
16.8% among recipients of liver allografts maintained 
on CsA-based immunosuppressive therapy.3'5,26,27 The 
use of azathioprine is associated with a significantly 
lower incidence of CR.7 The results from our center 
and multicenter trials have suggested that CR can be 
successfully treated by conversion to tacrolimus-based 
immunosuppression. I3-!7 
In our present series, CR occurred in 3,1% of the 
total patient population (32 of 1,048 patients), This 
condition improved significantly in 40.6% of patients 
(13 of 32 patients), mostly through optimization of the 
immunosuppressive regimen. Conversely, 19 patients 
(59.4%) experienced graft loss. Seven patients (21.9%) 
received a second allograft, and 12 patients (37.5%) 
died. A primary diagnosis ofPBC, PSC, or AIH; previ-
ous history of acute rejection episodes andlor CMV 
hepatitis; and older donor age were among the identi-
fied risk factors for the development of CR. Patients 
infected with HBV or HCV were also at greater risk. 
Lower serum bilirubin levels (P = .05) at the time of 
diagnosis and absence of HBV or HCV infection were 
among the factors favorable to a recovery from CR, 
Associations between primary diagnosis and the 
incidence of CR appear in the literature,28 An increased 
incidence of CR among patients infected with HBV, 
HCV, or CMV has been reported previously by our 
center29•31 and others. 52-55 
The incidence of CR also has been reported to be 
greater among patients with PBe, PSe, or AIH. In 
1988, we reported a greater incidence of CR among 
patients with PBC maintained on a CsA-based immu-
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nosuppressive regimen. 36 Candinas et al37 and others38 
reported that AIH and PBC are risk factors for the 
development of CR. In another blinded study, Hub-
scher et aP9 reported histopathologic features of recur-
rence of PBC in 16% of patients, including duct dam-
age, ductopenia, and portal fibrosis. Some of these 
findings are at least suggestive of a diagnosis of liver 
allograft CR. 
Similarly, histopathologic characteristics of PSC 
recurrence can be similar to CR.40,41 In the present 
series, we observed the development of CR in 3.7% of 
patients (3 of 81 patients) with a primary diagnosis of 
PSC. 
The present data confirm the association between 
primary diagnosis and the development of CR in a 
larger patient population followed up long term. Of the 
32 patients in our series who developed CR, 25 patients 
(78.1 %) had a primary diagnosis of HCV, HBV, PBC, 
PSC, or AIH. Specifically, 4.2% of patients (13 of 312 
patients) diagnosed with HBV or HCV developed CR, 
whereas 5.5% of patients (12 of 217 patients) with 
PBC, PSC, or AIH were diagnosed with CR. Relative 
risk for developing CR for patients with HBV and 
HCV infection was 3.2 times greater, and for patients 
with PBC, PSC, and AIH, 4.3 times greater compared 
with patients who did not have HBV, HCV, PBC, 
PSc, or AIH. In children, in whom the incidence of 
HBV, HCV, PSC, PBC, and AIH is lower than that in 
adults, graft loss from CR is also less frequent and 
occurs mostly when immunosuppression is discontin-
ued to control posttransplant lymphoproliferative dis-
order or in noncompliant teenagers. 12,42,43 
Rapid reduction or discontinuation of baseline 
immunosuppression for a compelling clinical condition 
or patient noncompliance imparts a significant risk for 
the development of CR. 43,44 The 7 patients in group III 
had a reduction in baseline immunosuppression, which 
was found to be the single most important cause of CR 
in 44% of patients who developed this condition. 
A direct link between acute rejection and CR was 
reported by Hyashi et al,45 who observed that a greater 
incidence of acute cellular rejection could lead to the 
development of CR among patients with autoimmune 
liver disease. Similarly, Kemnitz et al46•47 reported that 
irreversible bile duct injury might occur in patients with 
recurrent AIH who experience acute rejection episodes. 
In a recent review, Wiesner et aP6 identified a previous 
history of acute rejection episodes as a risk factor for the 
development of CR. 
Our data support a relationship between acute rejec-
tion and CR: 50% of patients with CR had experienced 
2 or more episodes of acute rejection. This is signifi-
cantly greater than that observed in patients who did 
not develop CR. In addition, mean donor age was older 
among patients with CR, corroborating previous find-
ings of overall poor outcome among recipients of older 
organ allografts.48,49 It is possible that older donors have 
preexisting arteriopathy in the allograft and the biliary 
epithelium is more susceptible to immunologic 
insult. 50 
Several reports have found a relationship between 
HLA antigen matching andlor mismatching, positive 
lymphocytotoxic cross-matching, and the development 
ofliver allograft CR.30,31,Sl-55 In this study, these factors 
did not predispose to the development of CR. In sum-
mary, the incidence of CR is low among patients main-
tained long term on tacrolimus-based therapy. For 
those patients who develop CR, a combination of risk 
factors appears to be involved, including a primary 
diagnosis ofPBC, PSC, or AIH; history of acute rejec-
tion episodes; CMV hepatitis; and older donor age. 
Lower serum bilirubin levels, absence of HCV andlor 
HBV infection, and lack of arteriopathy or duct loss on 
liver allograft biopsy proved to be useful parameters to 
distinguish between patients who could potentially 
recover from CR and those likely to require re-L T. 
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